A novel cardioprotective drug, K201 (JTV519), induces prolongation of QT and QTc intervals, but not torsades de pointes

Dokkyo Journal of Medical Sciences

Volumn 33, Issue 1, 2006, Pages 17-24

  Matsuda, Toshiya ^a   Matsuda, Ryuko ^a   Taguchi, Isao ^a   Toyoda, Shigeru ^a   Kikuchi, Migaku ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

K201 (JTV 519); QT interval; QTc interval; Ryanodine receptor; Torsades de pointes

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; CALCIUM ION; CHLORALOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; HEART PROTECTION; MALE; NONHUMAN; QT INTERVAL; QT PROLONGATION; RABBIT; SARCOPLASMIC RETICULUM; TORSADE DES POINTES;

EID: 33845754622     PISSN: 03855023     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bednar MM, Harrigan EP, Anziano RJ, et al: The QT interval. Prog Cardiovasc Dis, 43(suppl 1): 1-45, 2001.
2. Thibault B, Nattel S.: Optimal management with class I and class III antiarrhythmic drugs should be done in the outpatient setting: protagonist. J Cardiovasc Electrophysiol, 10: 472-481, 1999.
3. Kaneko N.: New 1, 4-benzothiazepine derivative, K201, demonstrates cardioprotective effects against sudden cardiac cell death and intracellular calcium blocking action. Drug Dev Res, 33: 429-438, 1994.
4. Inagaki K, Kihara Y, Hayashida W, et al: Anti-ischemic effect of a novel cardioprotective agent, JTV519, is mediated through specific activation of 5-isoform of protein kinase C in rat ventricular myocardium. Circulation, 101: 797-804, 2000.
5. Ito K, Shigematsu T, Sato T, et al: JTV-519, a novel cardioprotective agent, improves the contractile recovery after ischaemia-reperfusion in coronary perfused guinea-pig ventricular muscles. Br J Pharmacol, 130: 767-776, 2000.
6. Kimura J, Kawahara M, Sakai E, et al: Effects of a novel cardioprotective drug, JTV-519, on membrane currents of guinea pig ventricular myocytes. Jpn J Pharmacol, 79: 275-281, 1999.
7. + current in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol, 361: 646-653, 2000.
8. Nakaya H, Furusawa Y, Ogura T, et al: Inhibitory effects of JTV-519, a novel cardioprotective drug, on potassium currents and experimental atrial fibrillation in guinea pig hearts. Br J Pharmacol, 131: 1363-1372, 2000.
9. Wehrens XH, Lehnart SE, Reiken SR, et al: Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science, 304: 292-296, 2004.
10. Wehrens XH, Marks AR.: Novel therapeutic approaches for heart failure by normalizing calcium cycling. Nat Rev Drug Discov, 3: 565-573, 2004.
11. 1-adrenoceptor stimulation. J Cardiovasc Pharmacol, 36: 728-736, 2000.
12. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart, 7: 353-370, 1920.
13. Mazur A, Roden DM, Anderson ME.: Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation, 100: 2437-2442, 1999.
14. Carlsson L, Almgren O, Duker G.: QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol, 16: 276-285, 1990.
15. Kumagai K, Nakashima H, Gondo N, Saku K.: Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J Cardiovasc Electrophysiol, 14: 880-884, 2003.
16. Kaneko N, Ago H, Matsuda R, et al: Crystal structure of annexin V with its ligand K-201 as a calcium channel activity inhibitor. J Mol Biol, 274: 16-20, 1997.
17. Singh BN.: Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol, 78(suppl 4A): 41-53, 1996.
18. Nobe S, Aomine M, Arita M.: Bepridil prolongs the action potential duration of guinea pig ventricular muscle only at rapid rates of stimulation. Gen Pharmacol, 24: 1187-1196, 1993.
19. Hondeghem LM, Carlsson L, Duker G.: Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation, 103: 2004-2013, 2001.
20. Torres V, Tepper D, Flowers D, et al: QT prolongation and the antiarrhythmic efficacy of amiodarone. J Am Coll Cardiol, 7: 142-147, 1986.
21. Kohno M, Yano M, Kobayashi S, et al: A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol, 284: H1035-H1042, 2003.